MariaFleseriuMDFACE
Endocrinology • Portland, ORAdrenal Disease, Pituitary Disorders & Neuroendocrinology
Professor, Medicine (Endocrinology) and Neurological Surgery, Director Pituitary Center, Oregon Health and Science University
Dr. Fleseriu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3303 SW Bond Ave CH8N
Portland, OR 97239Phone+1 503-494-4314Fax+1 503-346-6810
Summary
- Maria Fleseriu, M.D., F.A.C.E., is an endocrinologist and the director of the OHSU Pituitary Center.
Education & Training
Cleveland Clinic FoundationFellowship, Endocrinology, Diabetes, and Metabolism, 2004 - 2006
The MetroHealth System/Case Western Reserve UniversityResidency, Internal Medicine, 2002 - 2004
University of Medicine and Pharmacy TimisoaraClass of 1993
Certifications & Licensure
OR State Medical License 2006 - 2025
WA State Medical License 2022 - 2025
OH State Medical License 2002 - 2006- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- Fellow (FACE) American Association of Clinical Endocrinology
Clinical Trials
- Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Start of enrollment: 2011 Nov 04
- An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Start of enrollment: 2011 Aug 16
- Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Start of enrollment: 2014 Mar 06
- Join now to see all
Publications & Presentations
PubMed
- Osilodrostat treatment in patients with Cushing's disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4).Akira Shimatsu, Beverly Mk Biller, Maria Fleseriu, Rosario Pivonello, Eun Jig Lee
Endocrine Journal. 2024-12-02 - 2 citationsHypopituitarism and bone disease: pathophysiology, diagnosis and treatment outcomes.Amit Akirov, Yaron Rudman, Maria Fleseriu
Pituitary. 2024-12-01 - Acromegaly and COVID-19, lessons, and new opportunities.Elena V Varlamov, Maria Fleseriu
Pituitary. 2024-12-01
Journal Articles
- Changes in Plasma ACTH Levels and Corticotroph Tumor Size in Patients With Cushing's Disease During Long-term Treatment With the Glucocorticoid Receptor Antagonist Mif...Maria Fleseriu,corresponding author James W. Findling, Christian A. Koch, Sven-Martin Schlaffer, Michael Buchfelder, and Coleman Gross, J Clin Endocrinol Metab
- Graves Disease Exacerbation After Pituitary Adenomectomy for Cushing Disease Resulting in an Adrenal CrisisK. Aktas, Mehmet and Fleseriu, Maria and J. Weil, Robert and Faiman, Charles and T. Sergev, Orlin and Reddy, Sethu and Hamrahian, Amir, The Endocrinologist
- Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An UpdateMaria Fleseriu, MD, Endocrine Reviews
- Join now to see all
Lectures
- New Types of Hypophysitis: Current Knowledge in Diagnosis and Management (Repeat)ENDO 2019 - New Orleans, LA - 3/26/2019
- Guided Posters: Neuroendocrinology and PituitaryENDO 2019 - New Orleans, LA - 3/23/2019
- New Types of Hypophysitis: Current Knowledge in Diagnosis and ManagementENDO 2019 - New Orleans, LA - 3/26/2019
- Join now to see all
Press Mentions
A Step-by-Step Guide for Diagnosing Cushing SyndromeAugust 23rd, 2024- Oral Octreotide in Patients with AcromegalyAugust 14th, 2024
- Clinical Trials Testing Osilodrostat for the Treatment of Cushing’s DiseaseJuly 25th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
